In this issue:
Non-smokers with NSCLC derive less benefit from front-line pembrolizumab
Superior survival with laparoscopic vs open surgery for rectal cancer
Cancer patients have an elevated risk of death from COVID
ORIENT-15: Sintilimab/ chemotherapy extends survival in ESCC
Pembrolizumab for MSI-H/dMMR metastatic CRC
Pembrolizumab may be an option for advanced anal cancer
Savolitinib has clinical activity in MET aberrant advanced solid tumours
Increased risk of breakthrough COVID-19 infections in patients with cancer
Anamorelin improves cancer cachexia
Metformin may mitigates the risk of poor CRC outcomes in diabetics
Please login below to download this issue (PDF)